Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Multiple sclerosis patients to have routine access to beta interferon drug, says NICE

Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance. 

Multiple sclerosis drug, Extavia, has been approved for routine funding on the NHS, in NICE draft guidance. A discount to the price of this drug now means it can be recommended as a cost effective option for adults with relapsing- remitting multiple sclerosis (MS) or secondary progressive MS with continued relapses. Affecting around 116,000 people in England, MS is a chronic and disabling condition affecting the brain and spinal cord. Relapse-remitting MS is where people have distinct symptoms, such as vision problems or difficulty keeping balance, which then fade away either partially or completely. Secondary progressive MS is the stage

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy